In the complex machinery of the American healthcare system, trust is the primary lubricant. We trust that when a doctor writes a prescription, it is necessary. We trust that when a pharmacy bills the government, it has actually provided a service. However, a landmark whistleblower case settled in late 2024 (and finalized for public record in early 2025) involving retail giant Walgreens has once again pulled back the curtain on how systemic “glitches” can lead to massive taxpayer losses.
The case, often referred to under the umbrella of U.S. et al. v. Walgreens, Case No. 1:18-cv-05452 centered on a simple but devastating allegation: Walgreens billed the government for millions of prescriptions that were never actually picked up by patients.
The Heart of the Case: Prescriptions for “Ghost” Patients
At its core, the lawsuit alleged that between 2009 and 2020, Walgreens knowingly submitted false claims for payment to Medicare, Medicaid, and TRICARE (the healthcare program for uniformed service members).
When a patient’s doctor sends a prescription to a pharmacy, the pharmacy often “fills” it in their system and bills the insurance provider immediately. However, if the patient never comes to the counter to collect the medication, the pharmacy is legally and ethically required to reverse that claim and return the money to the insurer.
According to the Department of Justice (DOJ), Walgreens failed to do this on a massive scale. For over a decade, the company allegedly pocketed tens of millions of dollars for medications that remained sitting on their shelves or were eventually restocked and sold to someone else—effectively “double-dipping” on the same bottle of pills.
The Role of the Whistleblowers
This wasn’t a discovery made by a routine government audit. Instead, it was brought to light by the bravery of insiders who saw the discrepancy and refused to stay silent. Two primary whistleblowers—known in legal terms as “relators”—filed qui tam lawsuits:
- Steven Turck: A former Walgreens pharmacy manager who witnessed the billing discrepancies firsthand.
- Andrew Bustos: A former district pharmacy supervisor who noticed systemic issues in how Medicare Part B was being handled.
Under the False Claims Act, private citizens with evidence of fraud against the government can sue on the government’s behalf. If the case is successful, the whistleblowers are entitled to a percentage of the recovery as a reward for their risk and information.
“We will not allow companies to hide behind their implementation of ill-conceived technology and systems that result in billing federal healthcare programs for goods and services never provided to beneficiaries.” — U.S. Attorney Damien M. Diggs
The “Software Error” Defense
When the allegations came to light, Walgreens did not admit to intentional fraud. Instead, the company pointed to a flaw in its proprietary pharmacy management software, Intercom Plus (IC+).
The company explained that the system was designed to remove “uncollected” prescriptions from the local store’s view after 29 days to save digital space. These prescriptions were moved to an “Unaccounted-For Status” on a central server. Because store-level pharmacists could no longer see these entries, there was no prompt to reverse the insurance claim.
While the government acknowledged that Walgreens eventually self-reported some of these issues in 2020 and cooperated with the investigation, the settlement highlights a critical legal standard: “knowingly” submitting false claims includes “deliberate ignorance” or “reckless disregard” for the truth. For a company of Walgreens’ size, letting a “glitch” persist for 11 years crossed the line from a mistake into a multi-million dollar liability.
Breakdown of the $106.8 Million Settlement
The financial resolution of this case was a multi-layered effort to make the taxpayers whole:
- Total Settlement: $106.8 Million.
- Federal Share: Approximately $91.9 million returned to the U.S. government.
- State Share: Approximately $14.9 million distributed among various states to settle Medicaid-related losses.
- Whistleblower Awards: For his pivotal role, Steven Turck was awarded nearly $15 million, while Andrew Bustos received over $1.6 million.
It is important to note that Walgreens had already refunded roughly $66 million prior to the final settlement, which was credited toward their total balance.
A Secondary Legal Storm: The Opioid Connection
While the January 2024 timeframe is synonymous with the “undispensed drugs” settlement, Walgreens was simultaneously battling a much larger legal fire. In early 2025, the DOJ announced a separate $300 million to $350 million settlement regarding the unlawful dispensing of opioids.
In that case, whistleblowers (also former pharmacists) alleged that Walgreens pressured staff to fill prescriptions quickly, ignoring “red flags” like excessive quantities or “the trinity”—a dangerous combination of an opioid, a benzodiazepine, and a muscle relaxant. This secondary case reinforces a theme seen in the first: a corporate culture that allegedly prioritized speed and volume over compliance and patient safety.
Why This Case Matters for Every American
You might wonder how a billing dispute between a massive corporation and the government affects your daily life. The implications are actually quite personal:
- Taxpayer Burden: Every dollar lost to healthcare fraud is a dollar taken away from improving the quality of care or reducing the national deficit.
- System Integrity: When pharmacies bill for drugs not dispensed, it creates a false medical record for the patient. A patient’s history might show they are taking a medication they never actually received, which could lead to dangerous drug interactions if a doctor relies on that incorrect data.
- Pharmacist Autonomy: These cases highlight the immense pressure retail pharmacists face. When corporate quotas and software limitations dictate the workflow, the “final check” on safety and legality can be compromised.
The Future of Pharmacy Compliance
As a result of these settlements, Walgreens has entered into a Corporate Integrity Agreement (CIA) with the Department of Health and Human Services. This means for the next several years, their billing practices and opioid dispensing protocols will be under a microscope. They have also implemented significant updates to their IC+ software to ensure that “lost” prescriptions are automatically reversed.
The Hidden Hand: The Role of PBMs
While the whistleblower case focuses on Walgreens’ internal software and billing, the broader context involves the invisible giants of healthcare: Pharmacy Benefit Managers (PBMs).
PBMs like CVS Caremark, Express Scripts, and OptumRx act as the intermediaries between insurance companies, drug manufacturers, and pharmacies. They are responsible for:
- Developing Formularies: Deciding which drugs are covered by your insurance.
- Negotiating Rebates: Getting discounts from drug makers.
- Setting Reimbursement Rates: Deciding how much a pharmacy like Walgreens gets paid for a specific pill.
Why the Relationship is Strained
The tension between Walgreens and PBMs often trickles down to the “ghost billing” issues seen in this case. PBMs often reimburse pharmacies at rates so low—sometimes below the actual cost of the drug—that pharmacies are under immense pressure to find every possible penny of revenue.
In the case of U.S. v. Walgreens, the failure to reverse claims for uncollected drugs meant Walgreens kept money that technically belonged to the PBMs (and by extension, the government). Furthermore, another major 2024 legal battle involved Walgreens allegedly “overcharging” PBMs by not offering them the same low prices given to members of the Walgreens Prescription Savings Club.
PBMs' Spread Pricing: The Hidden 'Middleman' Tax in Healthcare
For the average consumer, the PBM-Pharmacy relationship is a double-edged sword. While PBMs claim they use their size to lower drug prices, critics—and recent lawsuits—allege that their lack of transparency and “spread pricing” (charging the insurer more than they pay the pharmacy) actually drives up the total cost of healthcare. When a pharmacy like Walgreens fails to return funds for a prescription you never picked up, it’s one more “leak” in a system already overflowing with complex, hidden fees.
Summary of the “Ghost Billing” Settlement
| Feature | Details |
| Total Fine | $106.8 Million |
| The Violation | Billed Medicare/Medicaid for drugs never picked up by patients. |
| The “Glitch” | IC+ software hid uncollected prescriptions after 29 days. |
| Whistleblower Payout | Steven Turck received ~$15M; Andrew Bustos received ~$1.6M. |
| PBM Context | Occurred amidst wider disputes over “Usual & Customary” pricing. |
Conclusion
The U.S. et al. v. Walgreens case serves as a stark reminder that in the world of big-data healthcare, “oops” is not a valid legal defense. Whether the cause is a software bug or a deliberate choice to ignore red flags, the consequences of mismanaging federal funds are steep.
More importantly, it vindicates the role of the whistleblower. Without insiders like Steven Turck and Andrew Bustos, billions of dollars in fraudulent billing across the industry might continue indefinitely, hidden in the “unaccounted-for” corners of corporate servers.